Latest News
News
Denosumab indication now includes multiple myeloma, Amgen announces
Denosumab, which is not cleared through the kidneys, offers multiple myeloma patients bone protection with a convenient subcutaneous...
From the Journals
Continue to opt for HDT/ASCT for multiple myeloma
A systematic review and meta-analysis confirms that HDT/ASCT is still the best option for newly-diagnosed multiple myeloma.
News
FDA grants breakthrough therapy designation for severe aplastic anemia drug
Eltrombopag, from Novartis, will get expedited review for first-line treatment of severe aplastic anemia. It is already approved as a second-line...
Feature
California tops state tobacco prevention spending
Nationwide, most of the money from the 1998 tobacco settlement and taxes is going elsewhere in 2018.
From the Journals
Government insurance linked with lower likelihood of radiation therapy for limited-stage small cell lung cancer
Medicare/Medicaid had no impact on chemotherapy administration but was independently associated with lower likelihood of radiation therapy...
From the Journals
A mismatched haplotype may improve outcomes in second BMT
Mortality risk was highest in patients who had progressive or refractory disease before a second transplant, or who relapsed within 6 months of a...
From the Journals
Study: Test carcinoembryonic antigen in colon cancer after surgery
Researchers suggest that a recommended preoperative measurement actually provides more predictive value postoperatively.
From the Journals
Mutations linked to checkpoint inhibitor response in RCC
Researchers find potential way to predict immunotherapy responsiveness in renal cell carcinoma and other cancers.
Conference Coverage
DNA sequencing could help identify relapse risk in treated AML
ATLANTA – Study uses next-generation DNA sequencing to predict risk of relapse in AML.
From the Journals
Analysis: Hospital pay for performance not significantly improving Medicare outcomes
“Policymakers in the [United States] should consider one of two things: revise the current program or potentially end it.”
From the Journals
Autologous stem-cell transplantation for scleroderma beats cyclophosphamide in long term
Hematopoietic toxicity should be weighed against the benefits of transplantation.